Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
T.MAN Pharmaceutical PCLBKK:TMAN 21 EV-to-FCF is 56.53 as of Aug. 02, 2026, which is 240% above its 10-year median of 16.65. GuruFocus rates BKK:TMAN with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 571 Drug Manufacturers companies, T.MAN Pharmaceutical PCL ranks worse than 76.71% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, T.MAN Pharmaceutical PCL's Enterprise Value is ฿4,525 Mil.
T.MAN Pharmaceutical PCL's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ฿80 Mil. Therefore, T.MAN Pharmaceutical PCL's EV-to-FCF for today is 56.53.
The historical rank and industry rank for T.MAN Pharmaceutical PCL's EV-to-FCF or its related term are showing as below:
BKK:TMAN'
s EV-to-FCF Range Over the Past 10 Years
Min: 12.67 Med: 16.65 Max: 64.75
Current: 56.53
During the past 4 years, the highest EV-to-FCF of T.MAN Pharmaceutical PCL was 64.75. The lowest was 12.67. And the median was 16.65.
BKK:TMAN's EV-to-FCF is ranked worse than 76.71% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.66
vs BKK:TMAN: 56.53
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
T.MAN Pharmaceutical PCL's PE Ratio (TTM) for today is calculated as:
T.MAN Pharmaceutical PCL's share price for today is ฿11.30.
T.MAN Pharmaceutical PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿1.294.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
T.MAN Pharmaceutical PCL EV-to-FCF Related Terms
T.MAN Pharmaceutical PCL EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, T.MAN Pharmaceutical PCL's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
T.MAN Pharmaceutical PCL EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, T.MAN Pharmaceutical PCL's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where T.MAN Pharmaceutical PCL's EV-to-FCF falls into.
T.MAN Pharmaceutical PCL's current Enterprise Value is ฿4,525 Mil.
T.MAN Pharmaceutical PCL's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿80 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
T.MAN Pharmaceutical PCL (BKK:TMAN) has a EV-to-FCF of 56.53 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on T.MAN Pharmaceutical PCL and its competitors. This is 240% above median its historical median of 16.65. Over the past decade, T.MAN Pharmaceutical PCL's EV-to-FCF has ranged from 12.67 to 64.75. According to the industry distribution chart, T.MAN Pharmaceutical PCL ranks #438 out of 571 companies in the Drug Manufacturers industry, placing it in the top 76.7%.
Is T.MAN Pharmaceutical PCL's EV-to-FCF too high?
T.MAN Pharmaceutical PCL's current EV-to-FCF of 56.53 is 240% above median its 10-year median of 16.65. Over the past 10 years, this metric has ranged from a low of 12.67 to a high of 64.75. The Drug Manufacturers industry median EV-to-FCF is 20.66. T.MAN Pharmaceutical PCL's value of 56.53 is 173.6% above this industry median. Based on the distribution chart, T.MAN Pharmaceutical PCL ranks #438 out of 571 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, T.MAN Pharmaceutical PCL has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does T.MAN Pharmaceutical PCL's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, T.MAN Pharmaceutical PCL ranks #438 out of 571 companies for EV-to-FCF. This places T.MAN Pharmaceutical PCL in the lower half of its industry. The industry median EV-to-FCF is 20.66. T.MAN Pharmaceutical PCL's value of 56.53 is 173.6% above this benchmark. Historically, T.MAN Pharmaceutical PCL's own EV-to-FCF has ranged from 12.67 to 64.75 over the past decade. While the company's 10-year median is 16.65 vs. the industry median of 20.66, T.MAN Pharmaceutical PCL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.66, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. T.MAN Pharmaceutical PCL's current EV-to-FCF of 56.53 is 173.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on T.MAN Pharmaceutical PCL and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. T.MAN Pharmaceutical PCL's current EV-to-FCF is 56.53, which is 240% above median its own 10-year median of 16.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is T.MAN Pharmaceutical PCL stock overvalued right now?
T.MAN Pharmaceutical PCL (BKK:TMAN) has a current EV-to-FCF of 56.53. The current EV-to-FCF is 56.53, which is 240% above median its 10-year median of 16.65 and 173.6% above the Drug Manufacturers industry median of 20.66. T.MAN Pharmaceutical PCL's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For T.MAN Pharmaceutical PCL (BKK:TMAN), the current EV-to-FCF is 56.53 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
T.MAN Pharmaceutical PCL is engaged in purchasing, importing, manufacturing, and distributing original equipment and in manufacturing, distributing, and exporting modern medicines, traditional medicines, dietary supplements, and healthcare products for the healthcare industry. It offers products through brands such as T.Nutrition, T.Derma, Mommy&Me, TMT, Heaven Herb, and T.Pharmaceutical. The company's reportable segments are: Segment for manufactured products under own brand, which derives key revenue, Segment for manufactured products under third parties' brand, and Segment for trading products.
21GF Score
Get the complete analysis for BKK:TMAN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:TMAN has been successfully added to your 
